Skip to main content

Table 3 Treatment completion rate (Relative dose intensity ≥ 70%)

From: Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301

 

Group A (n = 45)

Group B (n = 45)

P value

6 months

38 (84.4%)

(95%CI; 70.5–93.5%)

29 (64.4%)

(95%CI; 48.8–78.1%)

0.052

9 months

34 (75.6%)

(95%CI; 60.5–87.1%)

26 (57.8%)

(95%CI; 42.2–72.3%)

0.117

12 months

31 (68.9%)

(95%CI; 53.4–81.8%)

20 (44.4%)

(95%CI; 29.6–60.0%)

0.033

  1. CI Confidence interval
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us